Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment

Journal of Psychiatric Research

Volumn 44, Issue 8, 2010, Pages 487-492

  Giegling, Ina ^a   Drago, Antonio ^b   Schäfer, Martin ^a,c   Möller, Hans Jürgen ^a   Rujescu, Dan ^a   Serretti, Alessandro ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Haloperidol; Plasma concentration; Psychotic disorders; Treatment outcome

Indexed keywords

HALOPERIDOL;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOSIS; SOLID PHASE EXTRACTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 77952891528     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.11.004     Document Type: Article

References (36)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 2003, 60:1228-1235.
2. Benson K., Hartz A.J. A comparison of observational studies and randomized, controlled trials. American Journal of Ophthalmology 2000, 130:688.
3. Bollini P., Pampallona S., Orza M.J., Adams M.E., Chalmers T.C. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine 1994, 24:307-316.
4. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain, C. Choosing between randomised and non-randomised studies: a systematic review. Health Technology Assessment 1998; 2(i-iv): 1-124..
5. Chang Y.C., Lane H.Y., Yang K.H., Huang C.L. Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 2006, 26:554-559.
6. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Research 2005, 76:247-265.
7. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 2000, 342:1887-1892.
8. Coryell W., Miller D.D., Perry P.J. Haloperidol plasma levels and dose optimization. American Journal of Psychiatry 1998, 155:48-53.
9. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
10. de Oliveira I.R., de Sena E.P., Pereira E.L., Miranda A.M., de Oliveira N.F., Ribeiro M.G., et al. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. Journal of Clinical Pharmacy and Therapeutics 1996, 21:229-236.
11. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 1992, 49:538-544.
12. Fitzgerald P.B., Kapur S., Remington G., Roy P., Zipursky R.B. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl) 2000, 149:1-5.
13. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000, 321:1371-1376.
14. Greene T. Randomized and observational studies in nephrology: how strong is the evidence?. American Journal of Kidney Diseases 2009, 53:377-388.
15. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Science 1995; 57: PL103-7.
16. Kapur S., Zipursky R., Roy P., Jones C., Remington G., Reed K., et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 1997, 131:148-152.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bulletin 1987, 13:261-276.
18. Lane H.Y., Lin H.N., Hwu H.G., Jann M., Hu W.H., Chang W.H. Haloperidol plasma concentrations in Taiwanese psychiatric patients. Journal of the Formosan Medical Association 1995, 94:671-678.
19. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bulletin 2004, 30:193-217.
20. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 2005, 57:1543-1549.
21. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry 2007, 68:352-360.
22. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica Supplement 2009, 7-14.
23. Lin C.H., Chou L.S., Hsu C.Y., Chen Y.S., Lane H.Y. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Journal of Clinical Psychiatry 2007, 68:1522-1527.
24. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 1993, 33:227-235.
25. Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M., Verhoeff N.P., Kerwin R.W. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychological Medicine 1993, 23:791-797.
26. Pocock S.J., Elbourne D.R. Randomized trials or observational tribulations?. New England Journal of Medicine 2000, 342:1907-1909.
27. Sacks H., Chalmers T.C., Smith H. Randomized versus historical controls for clinical trials. American Journal of Medicine 1982, 72:233-240.
28. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
29. StatSoft I. STATISTICA per Windows. StatSoft Italia srl; 1995.
30. Stroup S., Appelbaum P., Swartz M., Patel M., Davis S., Jeste D., et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research 2005, 80:1-8.
31. Tokunaga H., Kudo K., Imamura T., Jitsufuchi N., Ohtsuka Y., Ikeda N. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nihon Hoigaku Zasshi 1997, 51:417-422.
32. Ulrich S., Neuhof S., Braun V., Meyer F.P. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998, 31:163-169.
33. Volavka J., Cooper T., Czobor P., Bitter I., Meisner M., Laska E., et al. Haloperidol blood levels and clinical effects. Archives of General Psychiatry 1992, 49:354-361.
34. Volavka J., Cooper T.B., Czobor P., Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry 1995, 52:837-845.
35. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev 2002: CD001951.
36. Zimmerman M., Posternak M.A., Chelminski I. Symptom severity and exclusion from antidepressant efficacy trials. Journal of Clinical Psychopharmacology 2002, 22:610-614.